Compare Mercadolibre Inc (MELI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Novavax Inc — how do they compare? Mercadolibre Inc trades at $1,895 (market cap $94.13B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Mercadolibre Inc is far larger — about 51.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Mercadolibre Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and Novavax Inc for 59 Days on average.
| MELI | NVAX | |
|---|---|---|
Market Cap | $94.13B | $1.82B |
Volume | 273,781 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $12.56 |
52-Week Low | $1.55K | $6.22 |
Typical Hold Time | 117 Days | 59 Days |
Enterprise Value | $101.77B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,889.85, up 0.91% on the day, with a bullish technical signal and strong analyst support. Revenue grew to $28.89 billion in 2025, though net income margin dipped to 6.91%. The company is expanding its fintech ecosystem, with credit portfolio surging 75% to $16.4 billion in Q2 2026. Operating cash flow remains robust at $12.12 billion, supporting aggressive investment in logistics and market expansion across Latin America.
Outlook is positive given dominant market position and integrated e-commerce-fintech model, but valuation multiples like P/E of 50.51 suggest high growth expectations. Risks include macroeconomic pressures in key markets like Argentina and intense regional competition. Analyst consensus is strongly bullish with a $2,170 price target, indicating ~15% upside from current levels.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
